151 related articles for article (PubMed ID: 32811502)
1. Synergistic co-delivery of diacid metabolite of norcantharidin and ABT-737 based on folate-modified lipid bilayer-coated mesoporous silica nanoparticle against hepatic carcinoma.
Liu M; Tu J; Feng Y; Zhang J; Wu J
J Nanobiotechnology; 2020 Aug; 18(1):114. PubMed ID: 32811502
[TBL] [Abstract][Full Text] [Related]
2. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
[TBL] [Abstract][Full Text] [Related]
3. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
[TBL] [Abstract][Full Text] [Related]
4. Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Ren J; Li G; Zhao W; Lin L; Ye T
World J Gastroenterol; 2016 Apr; 22(15):3962-8. PubMed ID: 27099439
[TBL] [Abstract][Full Text] [Related]
5. Liquid chromatography-tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice.
Liu MC; Ma XQ; Xu Y; Peng LH; Han M; Gao JQ
J Pharm Biomed Anal; 2016 Feb; 119():76-83. PubMed ID: 26658337
[TBL] [Abstract][Full Text] [Related]
6. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
7. [Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells].
Chen X; Zhang XX; Li FF; Zhao YN; Jia Z; Gan Y; Li J
Yao Xue Xue Bao; 2014 May; 49(5):718-25. PubMed ID: 25151746
[TBL] [Abstract][Full Text] [Related]
8. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Choi JY; Ramasamy T; Kim SY; Kim J; Ku SK; Youn YS; Kim JR; Jeong JH; Choi HG; Yong CS; Kim JO
Acta Biomater; 2016 Jul; 39():94-105. PubMed ID: 27163403
[TBL] [Abstract][Full Text] [Related]
9. The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel.
Wang D; Huang J; Wang X; Yu Y; Zhang H; Chen Y; Liu J; Sun Z; Zou H; Sun D; Zhou G; Zhang G; Lu Y; Zhong Y
Biomaterials; 2013 Oct; 34(31):7662-73. PubMed ID: 23859657
[TBL] [Abstract][Full Text] [Related]
10. Promising positive liver targeting delivery system based on arabinogalactan-anchored polymeric micelles of norcantharidin.
Zhang Z; Yang L; Hou J; Xia X; Wang J; Ning Q; Jiang S
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S630-S640. PubMed ID: 30449176
[TBL] [Abstract][Full Text] [Related]
11. FAM46C is critical for the anti-proliferation and pro-apoptotic effects of norcantharidin in hepatocellular carcinoma cells.
Zhang QY; Yue XQ; Jiang YP; Han T; Xin HL
Sci Rep; 2017 Mar; 7(1):396. PubMed ID: 28341836
[TBL] [Abstract][Full Text] [Related]
12. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
[TBL] [Abstract][Full Text] [Related]
13. Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells.
Liang L; Zhao L; Wang Y; Wang Y
Mol Pharm; 2021 Mar; 18(3):1003-1013. PubMed ID: 33527831
[TBL] [Abstract][Full Text] [Related]
14. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound-Triggered Destruction of Folate-Functionalized Mesoporous Silica Nanoparticle-Loaded Microbubble for Targeted Tumor Therapy.
Lv Y; Cao Y; Li P; Liu J; Chen H; Hu W; Zhang L
Adv Healthc Mater; 2017 Sep; 6(18):. PubMed ID: 28671341
[TBL] [Abstract][Full Text] [Related]
16. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.
Guan M; Zhou Y; Zhu QL; Liu Y; Bei YY; Zhang XN; Zhang Q
Nanomedicine; 2012 Oct; 8(7):1172-81. PubMed ID: 22321383
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
Jiang S; Li M; Hu Y; Zhang Z; Lv H
Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
[TBL] [Abstract][Full Text] [Related]
19. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Valcourt DM; Dang MN; Scully MA; Day ES
ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
[TBL] [Abstract][Full Text] [Related]
20. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa.
Wang X; Gu Z; Li G; Zhang S; Cao Z; Yang Z; Liu G
Oncol Rep; 2014 Aug; 32(2):716-22. PubMed ID: 24891300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
